Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk

Katrin D. Mayer-Barber(National Institutes of Health), Alan Sher(National Institutes of Health)

Nature

June 25, 2014

10.1038/nature13489

Cited by 776

Related Papers

Successful T cell priming in B cell-deficient mice.

|The Journal of Experimental Medicine|1995|275

Effector Cells of Both Nonhemopoietic and Hemopoietic Origin Are Required for Interferon (IFN)-γ– and Tumor Necrosis Factor (TNF)-α–dependent Host Resistance to the Intracellular Pathogen, <i>Toxoplasma gondii </i>

|The Journal of Experimental Medicine|1999|244

Pharmacological Inhibition of Host Heme Oxygenase-1 Suppresses Mycobacterium tuberculosis Infection <i>In Vivo</i> by a Mechanism Dependent on T Lymphocytes

|mBio|2016|53

Heme oxygenase-1 inhibition promotes IFNγ- and NOS2-mediated control of Mycobacterium tuberculosis infection

|Mucosal Immunology|2020|33